Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Regulatory B cells (Bregs) are a subset of B lymphocytes with immunosuppressive functions, primarily through the secretion of anti-inflammatory cytokines such as IL-10, IL-35 and TGF-β. They play a critical role in maintaining immunological tolerance and preventing autoimmunity. Breg development is induced by inflammatory signals such as TLR ligands, BCR engagement and costimulatory molecules. Aberrant Breg function is implicated in various diseases, including autoimmune disorders, allergies, infections, cancer, and transplant rejection. While they hold therapeutic potential for suppressing excessive immune responses, safety concerns exist regarding their potential to promote infection or tumor growth.
N/A
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Regulatory B Cell (Breg).